Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Portfolio Pulse from
Akebia Therapeutics has reported its Q3 2024 financial results, highlighting the progress of its product Vafseo® (vadadustat), which is expected to be available in the U.S. market by January 2025. The drug is now covered for over 300,000 dialysis patients and has received TDAPA reimbursement and a Level II HCPCS code.
November 07, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akebia Therapeutics' Vafseo® (vadadustat) is on track for U.S. market availability in January 2025, with significant coverage for dialysis patients and regulatory progress.
The announcement of Vafseo's upcoming market availability and its coverage for a large patient base is a positive development for Akebia. The regulatory progress with TDAPA reimbursement and HCPCS code issuance further supports a favorable outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100